Australia's CSL gains on US tariff relief on key product imports

Shares of Australia's CSL Ltd CSL.AX rise as much as 2.8% to A$142.78, their biggest intraday pct gain since March 20, 2026

Australian biotech giant responds to U.S. administration's announcement on 2 April, intending to impose tariffs on pharmaceutical products imported to the U.S.

"Initial view is that most of CSL's U.S. product sales will not be subject to tariffs", says co

Says administration has recognised 'unique nature' of plasma-derived therapies under proclamation

Says unit CSL Seqirus' primary product sold in U.S. is Fluad, manufactured in UK, where tariff rate is presently 10%. Co expects this tariff will reduce to 0%

Stock down 18.5% YTD